Abstract Submission

1st ICEGH 2023 ABSTRACT SUBMISSION GUIDELINES

SHARE YOUR WORK WITH THE REGION’S LARGEST AUDIENCE

Presenting at ICEGH 2023 gives you the highest impact for your research and your career.

The act of submitting an abstract serves as a formal agreement by the author(s) to personally present

their work at ICEGH 2023, Makassar, South Sulawesi, Indonesia

Submission deadline is Friday, 22 September 2023, 12:00 noon (GMT+8).

It is advisable to begin drafting your abstract now to avoid the stress of last-minute peak submission times.

Submitting early will help you to bypass the rush around the deadline.

 

 

Abstract Submission Guidelines

Submission of abstracts should meet any of the following ICEGH topic areas:

  1. Prevention and Control of Disease
  2. Sustainability of Global Health system
  3. Health Policy and Managment
  4. Enviromental & Occupational Health
  5. Nutrition Epidemiology
  6. Big data and Digital Health
  7. Vaccine-preventable disease
  8. Social determinant of Health
  9. Reproductive and Population Health
  10. Biomolukuler and genetic of Public Health
  11. Healthy Settings and Healthy Cities
  12. Hospital and services management

Please kindle use the guidelines below for abstract submission of 1st ICEGH 2023

  • Only submit your abstract online using the form provided on the webpage, click here to access it, which must be filled out completely.
  • The abstract must be written in simple, accurate English with Times New Roman 12 font and one space between lines.
  • An abstract is a single paragraph that, in 250–300 words, briefly summaries the main ideas of the manuscript.
  • The title should be brief with no more than 20 words.
  • The first name, middle initial, and last name should appear at the top of the list of authors. There should be a comma between each author if there are multiple authors.
  • The background, purpose(s) or objective(s), methodology, findings, and conclusions of the study should all be clearly reflected in the abstract.
  • Tables, figures, abbreviations, acronyms, and references should not be included in the abstract.
  • Please include an alphabetical list of 3 to 5 keywords and the topic for indexing at the end of the abstract. Select the proper keywords because they will be used for later retrieval.
  • Please use the attached template for submission of the abstract.

Note:

The abstracts submitted are not parallel nor consecutively submitted for publications or presentations in other conferences

Indonesian COVID-19 pneumonia outcomes and cardiovascular disease: a multi-center cohort study

Indra Dwinata1*, Rosa Devitha Ayu1, Ryza Jazid Bahar2

1Department of Epidemiology, Faculty of Public Health, Universitas Hasanuddin, Makassar, Indonesia

2Center for Epidemiology and Population Health Study, Faculty of Public Health, Universitas Hasanuddin, Makassar, Indonesia

 

*Corresponding author

Indra Dwinata, Email: hisemailadress@gmail.com

Backgrounds: Indonesia is one of the 185 nations affected by the COVID-19 pandemic. Poorer clinical outcomes were associated with cardiovascular diseases (CVD) in COVID-19 participants. Due to the scant amount of data available in Indonesia, the association remained uncertain. The purpose of this study was to investigate the relationship between COVID-19 pneumonia patients’ CVD and clinical outcomes.

Methods: 584 adult COVID-19 pneumonia patients were enrolled in this retrospective cohort study in four Indonesian hospitals between September 2020 and July 2021. Non-CVD and CVD (hypertension, coronary artery disease, chronic heart failure, hypertensive heart disease, arrhythmia, cardiomegaly, left ventricular hypertrophy, mitral regurgitation, and myocardial damage) patients were divided into two categories. Clinical outcomes include inpatient mortality, admission to the intensive care unit, use of a ventilator, earlier death, and extended hospital stays. For analysis, the Mann-Whitney test was used.

Results: Hypertension was the most common CVD at 48.1%, followed by other CVDs like arrhythmia, myocardial Infarction (MI), coronary artery disease (CAD), congestive heart failure (CHF), hypertensive heart disease (HHD), and others. Patients spent a median of 12 days in the hospital, and the in-hospital death rate was 24%. MI had the highest risk of in-hospital mortality, especially in those with diabetes and chronic renal illness, while a longer hospital stay increased the risk for various CVDs, including hypertension, MI, CHF, diabetes, and cerebrovascular disease.

Conclusion: COVID-19 pneumonia in patients with CVD, specifically MI and hypertension, worsens the COVID-19 clinical outcomes. Patients with pre-existing cardiovascular conditions like MI and hypertension should receive close monitoring and early intervention when diagnosed with COVID-19 pneumonia, as it can worsen clinical outcomes.

Keywords: Covid-19, comorbidities; length of stay; preventive care; prognosis.

 

Abstract Template can be downloaded at the link below

Abstract Submission Guidelines